Listen old man.

I'm a dude that respects my elders. I'm also a dude that always tries to keep everything positive no matter what, hype everyone around me to keep them going, and not purposely cut anyone down. The world sucks enough without having people like that.

But we all have a line, and my line is my dog.

Kyle Bushnell / Townsquare Media

Because my dog is MY DUDE. We went through the tail end of my Tulsa, Oklahoma journey together. For emo reasons that I'll leave out of this story because it doesn't matter (plus who wants to read anything emo), that dog straight up saved my life.

I'm probably an annoying helicopter dog parent to him but whatever, I could be worse things. Which is why I'm calling you out for something you probably thought was funny in your head while you were running by my house on Saturday (which, honestly, props to you for still pounding the pavement like that because I don't do that now, let alone later in life like you are. So, good for you on that, but that's also the only compliment you're getting here.)

Townsquare Media

Before the weather turned to suck on Saturday, I was in the front yard doing some work with Remy tied to a tree right near me (which is ironic, now that I think about it, since I used to make fun of my parents for tying my toddler harness to a tree so I wouldn't wander off when I was a kid -- and here I was doing the same thing.)

What you don't know about Remy is that over the years, he's randomly ended up with some anxiety. While he loves humans, he goes on the defensive around other dogs. (Interestingly enough, he's totally chill around cats. But I digress.)

Every few minutes I'd take a break from the yard work to make sure he was good. Secure, not freaking out, living his best leashed-to-a-tree life. And he was. Even when a woman from another part of the neighborhood started jogging by him. His tail wagged, he started making his way over to her but the leash tightened, but he never lost excitement.

Townsquare Media

And, to her credit, seeing an excited dog near her path as she jogged closer and closer to us didn't phase her. You know what she did? She just smiled without breaking her stride. Even when he tried to jog next to her and was held back by the leash -- not one reaction to Remy.

Then, maybe 20 minutes later, you came. And you happened to come right when I was checking his leash and tightening it up a bit so he wouldn't end up having enough slack to reach the sidewalk or even worse, the road. But you couldn't just keep on jogging by like the woman before you did, could you?

No. Because as you started jogging by, you started barking like a dog at him. Taunting him. Enticing him. And not that Remy has ever shown a side that's even remotely close to vicious, but what the hell were you thinking? What was the purpose? So your ancient existence could feel like a comedian? You ain't Dr. Doolittle, bro.

Townsquare Media

What if I hadn't happened to be right with him when you ran by and did that? What if I was in another part of the yard, your barking put him on the defensive, and thinking he was protecting us, he got loose and went after you? Again, not that I've ever seen anything close to that from him, but you never know.

Then what, I have a lawsuit on my hands because it's 2023 and everyone sues for anything any chance they get (like Morgan Wallen getting sued for canceling a show), and maybe even have to put him down, all because you taunted him? Because you thought you were being funny?

Be smarter next time. You look like you've been around long enough to know better.

(And now that I'm at the end of this open letter, I feel like I just came off as the equivalent of a negatively stereotyped "crazy cat lady." Oh well, still hitting publish.)

Does your loyal pup's breed make the list? Read on to see if you'll be bragging to the neighbors about your dog's intellectual prowess the next time you take your fur baby out for a walk. Don't worry: Even if your dog's breed doesn't land on the list, that doesn't mean he's not a good boy--some traits simply can't be measured.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Excerpt from:
To the Total Suckbag Brunswick, Maine, Runner Who Taunted My Dog - WJBQ

Martin Dreyling, MD, Department of Internal Medicine III, LMU University Hospital Munich, in Germany, discusses the next steps for research with ibrutinib (Imbruvica) in the mantle cell lymphoma (MCL) space following the presentation of data from the phase 3 TRIANGLE study (NCT02858258).

A total of 870 patients were enrolled and randomized in the open-label TRIANGLE study between July 2016 and December 2020. Patients received either the previous standard treatment of 3 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone)/R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin) followed by ASCT (n = 288), the addition of ibrutinib to standard treatment (n = 292), or ibrutinib without ASCT (n = 290).

The median age among patients enrolled in the study was 57 years (range, 27-68). Additionally, 76% of the patients were male, and 87% had stage IV disease.

According to findings presented at the 2022 American Society of Hematology (ASH) Annual Meeting, adding ibrutinib to standard chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) and 2 years of maintenance ibrutinib showed that it could improve outcomes vs standard chemoimmunotherapy induction and ASCT alone for younger patients with MCL.

Dreyling notes that following these promising data, 2 randomized trials plan to be activated in which patients with MCL will be randomized to receive the new standard of chemotherapy plus ibrutinib or treatment with no chemotherapy.

Transcription:

0:08 | I think the next steps will be inclusion in the guidelines [and] as we now have proven, get rid of part of the chemotherapy. What about getting rid of chemotherapy overall, and therefore, this is our next step. We will activate 2 randomized trials during the next 6 months or so and both will be randomized trials between the new standard which is chemo plus ibrutinib vs a non-chemo arm. These results will be interesting, but that's to be reported in 3 to 4 years from now.

Read more from the original source:
Future Directions for MCL Following Results From the TRIANGLE ... - Targeted Oncology

Covina, May 02, 2023 (GLOBE NEWSWIRE) -- Cancer Stem Cells are subpopulation of cells within tumors with capacity of differentiation, self-renewal and tumorigenicity when transplanted in host of animal. Presence of major key players and agreement to develop cancer stem cell portfolio has driven market growth.

Rising prevalence of various cancer diseases has provided lucrative opportunities in target market growth. Growing demand for advanced treatment for cancer has given rise in research and development activities which in turn, propelled the demand for market growth. Improved medical research facilities is anticipated to increase the demand for Cancer Stem Cells market growth.

Key Highlights:

Request Sample Link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5090

Analyst View:Growing incidence of cancer diseases has become major factor in target market growth. Growing investment in research and development activities related to stem cell project has fruitful the demand for market growth. More research and development is needed to prevent bacterial infections and injection site reaction to provide lucrative growth in Cancer Stem Cells market in future. Report Scope:

Key players:

The key players operating in theCancer Stem Cells Market includes:

This report also examines significant market expansion influences, as well as opportunities, risks, and challenges facing significant businesses and the sector as a whole. The potential effects of important new developments on both current and future growth are also considered.

Request Free Pdf copy of the report: https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/5090

Browse in-depth TOC on Cancer Stem Cells Market60 Tables35 Figures140 Slides

What are some challenges faced by the Cancer Stem Cells Market Market?

What are the Drivers of the Cancer Stem Cells Market?

About Prophecy Market Insights:Prophecy Market Insights is a leading provider of market research services, offering insightful and actionable reports to clients across various industries. With a team of experienced analysts and researchers, Prophecy Market Insights provides accurate and reliable market intelligence, helping businesses make informed decisions and stay ahead of the competition. The company's research reports cover a wide range of topics, including industry trends, market size, growth opportunities, competitive landscape, and more. Prophecy Market Insights is committed to delivering high-quality research services that help clients achieve their strategic goals and objectives.

Other related Reports:

Read the original:
[Latest Version] Cancer Stem Cells Market is estimated to be US ... - GlobeNewswire

It starts with one, maybe two, grey hairs, and most people put it down to ageing without thinking about the process that turns their hair grey.

But a new study suggests stem cells may get stuck as hair ages, and lose their ability to mature and maintain hair colour.

Certain stem cells cells that are able to develop into many different cell types have a unique ability to move between growth compartments in hair follicles.

It is these cells that lose the ability to move with age, paving the way for grey hair.

Led by researchers from NYU Grossman School of Medicine, in New York, USA, the research focused on cells in the skin of mice and also found in humans called melanocyte stem cells, or McSCs.

The scientists suggested that if their findings hold true for humans, they could open up a potential way to reverse or prevent the greying of hair.

Hair colour is controlled by whether continually multiplying pools of McSCs within hair follicles (where hair grows from) get the signal to become mature cells that make the protein pigments responsible for colour.

Researchers found that during normal hair growth, such cells continually move back and forth as they transit between compartments of the developing hair follicle.

New treatments could lead to the reversal of hair going grey (Alamy/PA)

It is inside these compartments where McSCs are exposed to signals that influence maturity.

Specifically, the research team found that McSCs transform between their most primitive stem cell state and the next stage of their maturation, the transit-amplifying state, depending on their location.

According to the findings, as hair ages, sheds, and then repeatedly grows back, increasing numbers of McSCs get stuck in the stem cell compartment called the hair follicle bulge.

They remain there and do not mature into the transit-amplifying state, and do not travel back to their original location in the compartment, where they would have been prodded to regenerate into pigment cells.

Study lead investigator Qi Sun, a postdoctoral fellow at NYU Langone Health in New York, said: Our study adds to our basic understanding of how melanocyte stem cells work to colour hair.

Story continues

The newfound mechanisms raise the possibility that the same fixed-positioning of melanocyte stem cells may exist in humans.

If so, it presents a potential pathway for reversing or preventing the greying of human hair by helping jammed cells to move again between developing hair follicle compartments.

In the latest experiments in mice whose hair was physically aged by plucking and forced regrowth, the number of hair follicles with McSCs lodged in the follicle bulge increased from 15% before plucking to nearly half after forced ageing.

These cells remained incapable of regenerating or maturing into pigment-producing melanocytes, the study published in Nature found.

The stuck McSCs, the researchers found, ceased their regenerative behaviour as they were no longer exposed to much of the signalling that allowed them to produce pigment in new hair follicles, which continued to grow.

But other McSCs that continued to move back and forth between the follicle bulge and hair germ retained their ability to regenerate as McSCs, mature into melanocytes, and produce pigment over the study period of two years.

Study senior investigator Mayumi Ito, a professor in the Ronald O Perelman Department of Dermatology and the Department of Cell Biology at NYU Langone Health, said: It is the loss of chameleon-like function in melanocyte stem cells that may be responsible for greying and loss of hair colour.

The researchers plan to investigate means of restoring movement of McSCs or of physically moving them back to their germ compartment, where they can produce pigment.

View original post here:
Stem cells that get stuck may be the reason hair turns grey as people age - Yahoo News UK

Cyrus Khan, MD

Hematologist

Allegheny Health Network Cancer Institute

Pittsburgh, PA

CASE SUMMARY

A 43-year-old woman presented with fatigue and worsening, burning back pain. She had a medical history of mild hypertension that was well controlled with medication and her physical exam showed a 1.5-cm left posterior cervical node, a 2.5-cm right anterior cervical node, and a 2.0-cm left supraclavicular node. A CT scan of multiple enlarged mesenteric and retroperitoneal nodes showed that the largest measuring was 5.3 cm 3.1 cm.

Biopsy confirmed diffuse large B-cell lymphoma (DLBCL) and her immuno-histochemistry was positive for:

Her lactate dehydrogenase was within normal limits and she had an ECOG performance status of 0. Fluorescence in situ hybridization was negative for chromosomal abnormality, so R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) was initiated for 6 cycles and back pain resolved. Cerebrospinal fluid was negative for lymphoma and a posttreatment PET scan demonstrated a complete response (CR) with a Deauville score of 2.

DISCUSSION QUESTIONS

KHAN: Have you communicated with or worked with a CAR T center and then used certain therapies before the patients go on to cell collection, or even used bridging therapy?

BARSOUK: Im on the referring side, but if CAR T-cell therapy is not available now, while waiting it would not be uncommon to use a second-line therapy until the CAR T-cell therapy becomes available, then after collection of T cells, while the product is manufactured, that [second-line therapy] would be used. Unlike with stem-cell transplant, you dont need a strong CR or very good partial response. I dont think its required, correct me if Im wrong, for CAR T-cell therapy. So when it becomes available, the patient can proceed, right?

KHAN: Yes, you are right. You dont need to push the patient into a CR; you just need to control the disease so its not blowing up before we have the opportunity for all those things. Typically, what Ive seen in the community and [in my prior experience] would be drugs like gemcitabine [Infugem] plus oxaliplatin [Eloxatin; GemOx], and the newer therapies as well, of course.

FAROUN: To the question of if the patient is waiting for almost 2 months for CAR T-cell therapy, how to cool the disease off, it depends on the transplanter or the CAR T-cell center. Usually, I cool them off with either GemOx or even the anti-CD19 drug tafasitamab-cxix [Monjuvi].

I would like to use tafasitamab without lenalidomide [Revlimid] as lenalidomide might affect the recovery. Polatuzumab vedotin-piiq [Polivy] also could be used, but I dont know if you have any other options and these are the new medications that I use for bridging.

KHAN: Exactly, you are doing it right. Do you have an idea of how long it takes, over there, from T-cell collection to the infusion?

FAROUN: A year ago, we had a hard time, and recently we might have it within 30 to 45 days of collection.

CASE UPDATE

Eleven months after completion of therapy, the patient complained of fever, night sweats, and back pain. A palpable lymph node in left groin was discovered on physical examination. Another PET/CT scan showed a new left inguinal lymph node, increase in size of residual node, as well as multiple metabolically active lesions in lymph nodes of the retroperitoneum, abdomen, and pelvis.

A biopsy revealed DLBCL and the patient was referred to a transplant center. R-ICE (rituximab, ifosfamide (Ifex), carboplatin, and etoposide) salvage therapy was initiated, and a postsalvage PET/CT scan gave her a Deauville score of 5. The patient was referred for CAR T-cell therapy and was placed on a waiting list. The patient opted to continue receiving treatment locally while waiting for availability at a cellular therapy center.

KHAN: Does anybody else have a different experience? Has anybody seen a 3- or 4-month lag [when looking to use CAR T-cell therapy] or any [have seen] astounding speed [in getting it], maybe even within a month?

BARSOUK: Whats the manufacturing time of the product? In your experience, what is the variation?

KHAN: Well, 3 weeks is the soft standard. About 20 to 21 days is the time it takes, depending on how close the manufacturing center is to you and what the shipping time is. Typically, it takes about 3 weeks for the whole manufacturing process to take place.

FAROUN: The question that we have to ask ourselves and to ask you, as an expert in lymphoma, is what kind of bridging therapy do you use for patients who are candidates for CAR T-cell therapy?

KHAN: I typically have used either GemOx or single-agent polatuzumab, which is common. If you go to any center, these are the 2 most common regimens that people use.

DISCUSSION QUESTIONS

KHAN: The first question is important: Who is involved in the decision-making? Is it you recommending it? Do you work with a CAR T-cell center to make that call about what to give? Do you discuss it with the patient? Do logistics come into play?

SANDHU: Typically, after the first-line therapy, [we] refer these patients out to our main site for specialists, and we try to get that available for the patient locally. Initially, with the first relapse or refractory disease or a relapse within 12 months, I typically end up referring the [patient] for CAR T-cell therapy.

KHAN: And the treatment that you would give before CAR T-cell therapy, or for bridging, if you are helping locally, do you just take their recommendations in what you would use?

SANDHU: Yes, I typically take their recommendations and we usually end up using GemOx.

KHAN: Thats how we work, too, and that is the most common. Dr Faroun, have you used tafasitamab before CAR T-cell therapy?

FAROUN: Yes, I have experience with tafasitamab. Again, its indicated for patients who are not candidates for transplant or who were not cleared for CAR T-cell therapy later, but I think tafasitamab is a good regimen. However, the dose of lenalidomide is, in my opinion, prohibitive.

A lot of patients will end up with pancytopenia with 20 mg oral daily, 3 weeks on, 1 week off. So I back off, especially if the patient is old [or has some renal failure] and usually I start with 15 mg, or down to 10 mg, but I have never had any luck with 20 mg.

KHAN: Yes, youre right. The starting dose was 25 mg in the trial, and almost two-thirds of the patients required a dose reduction.1 So youre right: Especially in the beginning, when the tafasitamab is on the weekly schedule, its a little tough to tolerate everything.

Has anybody used polatuzumab, or polatuzumab plus bendamustine and rituximab [pola + BR], in that preCAR T stage, or for bridging, for example? Probably not. Ive used polatuzumab somewhat, too, and we talk about all these issues, but generally, we go by the NCCN guidelines.2

I think everybody takes patient preference and comorbidities into account. Has anybody come across a patient whom youve recommended for CAR T-cell therapy but, for whatever reason, they havent made it, or they dont want to go, and [you] just do something different?

VARADI: Yes. I had a patient who was referred and the patient and the patients family declined.

KHAN: What was that for? Was it because it was far, or they just didnt like the idea about the toxicity maybe? Or [something else]?

VARADI: I think it was mainly social issues.

KHAN: Do you remember what you chose to do with that patient, then?

VARADI: Its actually ongoing. He is getting rituximab plus GemOx and we are discussing with them, again, the CAR T-cell therapy option or maybe autologous bone marrow transplant.

KHAN: Got it, so trying to convince them still.

VARADI: But I cant force it.

KHAN: Yes, as it is with everyone. At least there are options now to keep things at bay until they can make that final decision.

CASE UPDATE

The patient received pola + BR.

DISCUSSION QUESTION

KHAN: Can anyone share [their] experience using [pola + BR]? Did the patient respond? Any toxicity issues? And I mean in any setting. It doesnt have to be in a preCAR T setting.

FAROUN: I have used it, again, according to the guidelines, in a third-line setting. So the only thing I see a lot with this regimen is neuropathy and the need for dose reduction. If the patient is a candidate for CAR T-cell therapy, I would not use this regimen with bendamustine; I use it [only] with rituximab.

KHAN: Thats how most of us would do it, too. For those of you who have used it, and for those of you who havent used it, do you have any reaction to these updated data [NCT02257567]?3

What stood out to you? Are there any surprising data that you saw in this? Have you had similar experiences, as far as the responses are concerned?

COSTELLO: In this relatively highly pretreated group, which had a fair number of comorbidities and they werent candidates for [autologous stem cell transplant] or [CAR T-cell] therapy, the response rates were pretty impressive, especially that CR rate [42.5%].3 I wish it were a more durable CR, but in this patient population, this is still an impressive number.

KHAN: Have you used pola + BR, by any chance?

COSTELLO: I have not yet, and many times, as other people have commented, as patients get into the second-line setting, we refer these patients to a tertiary center to consider CAR T-cell therapy, and these sorts of medicines often get treated, still, down at the tertiary center.

KHAN: Is there anybody else who has had a different experience or who was surprised by these data, or who has any other thoughts?

SAMHOURI: I like that high-risk patients are represented in the trials. We have a good number of patients with activated B-cell subtype, approximately half of them. We have approximately 80% with primary refractory disease, or at least who relapsed quickly, within 12 months.3 Those are the patients that are difficult to treat and putting the response rate and the long follow-up in context, it gives us a good option for treatment for patients, at least those who are not going for transplant or CAR T-cell therapy.

KHAN: Is there anybody who thinks its a great advantage to have just 6 cycles, not something that you have to continue for too long?

FAROUN: Yes, thats an advantage, 6 cycles and you stop, but the question is, to be honest with you, I am not that impressed with these data. The progression-free survival is only 9 months.3 I think we have better agents at this time, but not when the study was conducted. CAR T-cell therapy would be much better, in my opinion, and even tafasitamab is much better as a second-line therapy. I had some questions from the insurance company if the patient has CD79 [expression] on the malignant cells.

KHAN: Yes, they shouldnt [ask you], because CD79 is naturally expressed in everyone. So different experiences, and youve had a good experience with tafasitamab plus lenalidomide.

FARON: My question then is, is CD79 100% overexpressed on diffuse bulky cells?

KHAN: Yes, typically its like CD20, and most of the patients will have it expressed. [It is one of the B-cell markers.]

DISCUSSION QUESTIONS

KHAN: How do you manage [the adverse events (AEs)]? How do you manage cytopenias? How do you manage the peripheral neuropathy [From the Data3]?

BARSOUK: I havent used it, but I would do exactly what is [suggested] here. For significant thrombocytopenia or neutropenia, I would hold until [the patient] recovers to a certain level of platelets and then implement dose reduction. And the same goes for peripheral neuropathy.

KHAN: I follow some of these protocols and work with pharmacists and advanced practice providers, and they make sure we are keeping a closer eye on the labs, and everything, and treat them appropriately. But, yes, thats typically how we would follow these.

REFERENCES

1. Salles G, Duell J, Gonzlez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.Lancet Oncol. 2020;21(7):978-988. doi:10.1016/S1470-2045(20)30225-4

2. NCCN. Clinical Practice Guidelines in Oncology. B-cell lymphomas, version 2.2023. Accessed March 5, 2023. https://bit.ly/3YFDw8W

3. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.Blood Adv. 2022;6(2):533-543. doi:10.1182/bloodadvances.2021005794

See the original post here:
Roundtable Discussion: Khan Reviews Systemic Therapy for ... - Targeted Oncology

PRESS RELEASE

Published April 18, 2023

In 2022, the net worth of the global Canine Arthritis Treatment Market size was valued at US$ 2.39 Billion. It is projected that the demand for medications to treat canine arthritis will increase at a CAGR of 4.2%, resulting in a market valuation of US$ 3.05 Billion by 2028. In 2021, canine arthritis treatment medications held a 17.2% share of the global rare inflammatory disease treatment market.

Canine arthritis is a degenerative joint disease that causes inflammation in dogs joints due to constant rubbing, cartilage deterioration, and long-term joint problems. The most commonly affected joints in animals are the knees, elbows, shoulders, hips, and spine. Injuries, obesity, and poor bone formation are some of the causes of canine arthritis in dogs.

Get Sample [emailprotected] https://www.futuremarketinsights.com/reports/sample/rep-gb-3552

The global canine arthritis treatment market is expected to grow significantly during the forecast period, according to Future Market Insights, due to the increase in dog ownership worldwide, the development of veterinary healthcare infrastructure, and the expansion of treatment options for canine arthritis. The rising prevalence of obesity-induced arthritis among dogs and increased awareness about companion animal health are key factors driving this growth. Furthermore, the FDAs ease of approval for innovative and novel canine arthritis treatment drugs will create growth opportunities for market players.

Key Takeaways from Canine Arthritis Treatment Market Study

Get in Touch With Our Team For [emailprotected] https://www.futuremarketinsights.com/request-discount/rep-gb-3552

Competitive Landscape

Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading players in the canine arthritis treatment market. These manufacturers continue to dominate the market landscape of canine arthritis treatment by ensuring product availability, collaborating with the local distributors, strengthening manufacturing facilities, and strategizing R&D for diversification of product portfolio.

Key Segments Of Canine Arthritis Treatment Industry Survey

Canine Arthritis TreatmentMarketbyTreatment:

Canine Arthritis TreatmentMarketbyRoute of Administration:

Canine Arthritis TreatmentMarketbyDistribution Channel:

Request Report [emailprotected] https://www.futuremarketinsights.com/customization-available/rep-gb-3552

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5),we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact:

Future Market Insights, Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware 19713, USAT: +1-845-579-5705For Sales Enquiries:[emailprotected]Browse All Reports:https://www.futuremarketinsights.com/reportsLinkedIn|Twitter|Blogs

The post Canine Arthritis Treatment Market is anticipated to reach a valuation of US$ 3.05 Billion by 2028, at a CAGR 4.2% appeared first on Future Market Insights.

Visit link:
Canine Arthritis Treatment Market is anticipated to reach a valuation ... - Digital Journal

If you're partial to a scientific or technical way of thinking, you might be well-suited for a career in STEM, which stands for science, technology, engineering and mathematics.

The technology portion, in particular, is filled with pathways that require varying skills and experiences.

As rapid technological advances dictate the future of work, you may wonder how you can best prepare yourself for your first role in the field and the one after that.

Heres a guide to get you started.

The path into tech isnt a one-way street, but there are certain credentials and experiences that can make you more competitive, including a college degree and a combination of technical and soft skills.

To break into the tech field, youll want to earn at least a bachelors degree. To be a competitive candidate, a bachelors degreeis a must, said Ahlam Alhweiti, a senior software development engineer and information technology faculty member at Southern New Hampshire University (SNHU).

According to the U.S. Bureau of Labor Statistics (BLS), most computer and information technology occupations list a bachelors degree as the required entry-level education. However, Alhweiti said masters degreesare often preferred.

What you choose to major in can vary, though. Some bachelors degrees you might consider obtaining include:

If you cant commit to a full-time course load, you dont have to. SNHU faculty trainer and STEM adjunct Steve Villone completed some of his education part-time as he raised his family and built his career in tech.

And if you earn your degree online, you may find greater flexibilitythan at traditional brick-and-mortar colleges.

While you earn your college degree, you may have an opportunity to complete an internship. An internship allows you to gain hands-on experience inside an organization. Not only can this help you develop practical skills, but it can also add valuable experience to your resume and lead to more networking opportunities.

If you are a student, do at least one, if not two, internships, said Faryal Humkar, an SNHU career advisor who supports STEM students and alumni.

If youre already working full-time and going to school, you may wonder when youll have time to also complete an internship. Some schools allow you to turn your internship experiences into college credits, which can alleviate some of that stress. At SNHU, for example, you can often earn three credits toward your degree if you complete a set number of hours and a supplementary internship course that helps you connect your experiences to your education.

Humkar said employers are generally flexible with their interns, too, meaning you might be able to create a schedule that works for you and your supervisor. You may also have the option to complete a remote internship, meaning you dont need to travel to an office setting to gain professional experience.

If youre not having luck landing a posted internship, Humkar suggests creating your own. Almost everyone has a tech department these days, right? Your hospitals, your school district, city, colleges, anywhere just call and say, hey, I'm a full-time student. I'd love to do an internship with your department. Can I email you my resume? Humkar said. A lot of them will welcome you with open arms.

You might also consider volunteering at local nonprofits. The great thing about technology is that there are so many places that need help, said Brooke Goggin, a solutions engineer and computer science faculty member at SNHU. Although unpaid, you can still count these types of volunteer work as professional experiences.

Volunteer work can also help you grow your network. "You can make connections and have the opportunity to get good references that will benefit (you) in (your) job search," said Dave Numme, a senior associate dean of STEM programsat SNHU. "Also, nonprofits sometimes have difficulties having enough technology staff, so they frequently welcome additional help."

Relevant experiential learning opportunitiesdont just help you become a more appealing candidate; they can also help you determine what areas of technology interest you most.

Try to familiarize yourself with the various niches in technology, Villone, who has a background in programming, networking, cyber security and more, said. You dont have to be good at everything. Maybe you like SQL (database queries). Then follow that thread. Maybe you like forensic cyber security. Follow that thread.

While teaching a kinesiology course at a community college, Goggin saw an opportunity to automate a fitness center. In collaboration with two computer science students, she wrote a computer program that did just that.

That hands-on experience helped her get started in tech.

Technology micro-credentials are plentiful. A certificate programor certification can help you zero in on a particular area of technology that interests you, and they typically take less time to completethan a degree.

The trifecta of a degree, certification and experience really moves applicants to the front of the line, Goggin said.

Villone recommends earning one or more basic certifications, such as:

A good way to tell what certifications make sense for you is to review job listings for a position you want. (If) you continue to see CompTIA on job listings, you know you may want to... start working on that certification so that way it'll make you more competitive, Humkar said.

Some colleges, such as SNHU, may offer discounts for specific certifications, allowing you to save some money while obtaining the industry credential.

Having technical skills, sometimes called hard skills, is central to working in tech. But how do you know which ones youll need?

Beyond knowing how to navigate computers, cell phones and various operating systems, Goggin believes you should understand security, programming, networks, analytics and machine learning if you want to break into the tech field.

CompTIA breaks some of the most in-demand tech skills into five categories:

College degree programs cover many of these subjects, allowing you to study and develop your skills. Then, should you land an interview, you can describe how you have gained and applied skills in a bit more depth especially if you earned an A in the class, Humkar said.

No matter what field you go into, exercising soft skills can be valuable especially with the advancement of machine learning.

Certain soft skills are particularly helpful for a tech career. Alhweiti, Goggin and Villone stressed the importance of these, in particular:

You can display your soft skills during job interviews. For instance, the question Why should I hire you? can be met with a combination of verbal communication skills, problem-solving skills and more.

This is not (an) I think, or I feel, but instead I have these skills supported by these examples that will meet your companys mission in these ways, Goggin said.

Villone also offered the ability to let go as an important skill. This can help you move on in your career and avoid burnout. Being able to say, I did the best I could for now, and Im going to put this down for a while, This is not easy, Villone said. But it is a skill. It is a powerful skill.

Your college may have a team of trained professionals to support you as you achieve your professional goals. SNHU, for example, has career advisorsyou can work with as soon as youre enrolled, and they will be there for you even after youve joined the universitys alumni community.

Humkar, who is also a Certified Professional Resume Writer (CPRW), said that advisors like herself are available to help you explore your goals, build your resume, establish an online professional presence and navigate salary negotiations. They can help you prepare for interviews, too, and share other advice that may help you as you seek to establish and grow your career.

Some schools also have a career team dedicated to helping students interested in completing internships for college credits.

As technology continues to change and advance, so will the careers that interact with it. If you want to establish and grow your career in technology, you must be willing to keep up with the advancements. Sometimes this means earning new certifications. It could mean navigating search engines when you need to learn more about a particular subject or troubleshoot an issue youre having.

Having the ability to learn on your own is essential to working in the tech field, according to Goggin. Being able to problem solve and learn are crucial regardless of what skills you know, she said. Whatever skills you know, they will change quickly, so you will need to remain up-to-date and keep learning.

Following publications such as TechRepublic, PCMag and vendor blogs can be another good way to stay up-to-date on the latest tech news and insights, according to Numme. You can also find podcasts and tech forums that will support your ongoing education.

Taking initiative in the workplace and going above and beyond can also help you leave a good impression on your internship supervisor or employer. If youve completed your assigned tasks or observed a pain point on your team, Humkar suggests volunteering to help. For example, you could say to your manager: I noticed that ... so-and-so is a little overwhelmed, and I'm done with my work. Can I help them? This really shows initiative and employers like this, Humkar said.

While youll probably learn a lot on the job, its helpful to have foundational experiences and skills you can showcase as a job candidate that youll continue to build on once you land a role.

Experience comes in many shapes and forms, though from class projects to pet projects.

When youre ready to start applying for jobs, here are five entry-level careers to consider:

According to Numme, those working in this role build important sensitivities to the user experience and get an overview of the technology services with an organization. "In addition, doing this work allows them to see if (they have) an interest or aptitude in an area of specialization," Numme said. "This exposure can lead to other jobs."

Becoming a technology professional can take time and tenacity. Believe in yourself, leverage resources, develop your skills and keep learning. Do not let anyone tell you that you cannot do something, Villone said.

Between the evolving nature of the field and the multiple pathways available, a tech career could be worth it if its an area that interests you. Jobs in this field generally pay well, too. Per BLS data, the median salary for computer or information technology occupations was $97,430 in 2021 more than double the median wage for all occupations.

Additionally, theres increasing flexibility in the field to accommodate work/life balance, in Alhweitis experience. Most tech companies allow for working from home and adjusting work hours as needed, she said. Also, its very rewarding to work in an environment full of talented and innovative individuals and makes you learn quickly.

With all the advancements in the field, who knows where a career in tech could take you? It brought Goggin abroad for a year, where she implemented technology solutions at universities in France.

It is not an easy career, but the work is well worth it and think of the impact you can have, Goggin said. You might save people from a breach, a bug in a medical device or a bug in a bank that might cause people to lose money that is exciting.

Numme agrees that, as a tech professional, you can make a real difference in the world. "There are so many ways that technology has and will continue to improve the lives of others," he said. "Working in technology is an opportunity to ... make a positive impact for our fellow humans."

A degree can change your life. Find the SNHU technology programthat can best help you meet your goals.

Rebecca LeBoeuf 18 22G is a writer at Southern New Hampshire University. Connect with her on LinkedIn.

Read more:
How to Get Into Tech | SNHU - Southern New Hampshire University

Woman who was told she had tonsillitis correctly diagnosed herself with leukaemia - using GOOGLE

Duration: 00:42 3 days ago

A woman who was told she had tonsillitis correctly diagnosed herself with leukaemia - using Google. Chloe-Leigh Todd, 22, started experiencing a sore throat and general illness. One month after starting to feel unwell Chloe had a telephone appointment with her GP and was told she had tonsillitis. After googling her symptoms - which included vomiting, night sweats, and weight loss - Chloe realised she was suffering from textbook leukaemia symptoms. Chloe managed to have a face-to-face appointment where she went for a blood test. Her results came back abnormal and she went straight to the hospital where she was told she had leukaemia. Now she has been cancer-free for three years and is no longer having treatment, although still suffers with some side effects. Chloe Todd, 22, a stay-at-home mum from Gateshead, Tyne and Wear said: "Everyone knows their own body and I just knew it was something serious. "The doctors were putting it down to other things but I was adamant they were wrong. "I googled my symptoms - night sweats, fatigue, bruising and so on - and leukemia came up as the first search result. "I checked and saw I had every symptom on the whole website - everyone had thought I was crazy when I said it but I knew I wasn't. "When the doctor confirmed it, I thought I was going to die. In June 2020 after being told she had tonsillitis, Chloe managed to get herself a face-to-face appointment with a doctor because she thought they were wrong. The mum of one had been suffering from a sore throat, night sweats, vomiting and weight loss since February and was getting concerned so searched online for answers. After having a blood test, Chloe was called by the doctors and told her results were abnormal and called into the hospital where she was told she had leukaemia and was "weeks away from death". The following day Chloe was sent to the Newcastle Freeman Hospital to start treatment. She said: "I had a bone marrow biopsy and told I was weeks away from death. "The cancer was everywhere in my blood. Doctors told me they didn't know if chemotherapy would help but they were willing to give it a try." Chloe endured six rounds of chemotherapy which eradicated most of the cancer, leaving her more optimistic. In September 2020, Chloe was put on the Anthony Nolan register in search for a bone marrow donor. Straight away the hospital found a 100% match in a 27-year-old boy, and she had the transplant in October 2020. This is done by transferring stem cells from one person to another, replacing damaged blood cells with healthy ones. After a successful operation, Chloe underwent another bone marrow biopsy to make sure her new cells had worked - later receiving the news she was cancer free. Leukaemia symptoms - skin looking pale or "washed out" - tiredness - breathlessness - losing weight without trying - frequent infections - having a high temperature, and feeling hot or shivery (fever) - night sweats - easily bruised skin

Send MSN Feedback

Please give an overall site rating:

Opens in a new window Opens an external site Opens an external site in a new window

Read the original:
Woman who was told she had tonsillitis correctly diagnosed herself ... - msnNOW

Maine is a hotspot for vacations in the summertime, even for locals. Our state is so massive with so much to offer that Mainers become tourists in their own state, visiting nooks and crannies, towns and cities they've never been to before.

Whether you're a tourist or a local, there are times when I'm sure you wish you could bring your furry friend on vacation with you.

Not all pets are travel-friendly but if you have a four-legged friend who loves to hit the road, does well in new places, and wants to go on an adventure, it should be able to come with you on your trip.

Luckily, there are plenty of pet-friendly lodging accommodations in Maine and scattered all around the state, so no matter where you choose to go, you'll be able to find a spot for you and your dog. Some spots even allow cats!

Not only do many places in the state offer pet-friendly accommodations but they also offer generous pet packages to make your pet as comfortable as possible during its stay.

At these spots in Maine, your pet is a respected and well-taken care of guest, just like you and the rest of your family.

From gorgeous Inns in coastal towns to cabins by the lake, you and your pets can have the ultimate vacation in Maine. Want to go kayaking on the lake? Your dog can come with you. Heading out for a hike? Grab the leash.

The weather is warming up, flowers are blooming, and the sun is shining here in Maine. Now is the perfect time to travel around Vacationland with your pets. Here are some places you can stay with them:

Take the whole family for a trip around Maine, even the four-legged members.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Go here to see the original:
Bring the Whole Family: 11 Pet-Friendly Lodging Options in Maine - WJBQ

What is Multiple Myeloma?

Multiple Myeloma, cancer of plasma cells is the second most common blood cancer around the world. Plasma cells are a type of white blood cells, which produce antibodies that protect the body from infection. They are found in the bone marrow, which is the spongy tissue seen in some bones.

In multiple myeloma, the plasma cells clone and proliferate excessively, displacing healthy bone marrow cells that produce red blood cells, platelets, and other types of white blood cells (WBC). This sets off a chain reaction of illnesses and disorders that can harm multiple organs like bones, kidneys, and the bodys capacity to produce healthy red, white, and platelet blood cells. Multiple organ systems are affected, hence the name.

It mainly affects adults in the age group of 65-70 years. Multiple myeloma presents with different kinds of symptoms which can resemble a lot of other conditions. Initially one may not experience any symptoms. This cancer does not cause any lump or tumour.

Some may not experience any symptoms and the condition may be accidental when blood or urine tests show abnormally high protein. This type is called smouldering myeloma.

Rarely, cancer cells concentrate in a particular bone or soft tissue, rather than involving many organs. This is called solitary myeloma/plasmacytoma.

The are many symptoms one can experience:

Researchers are yet to identify the exact cause of multiple myeloma. However, certain risk factors have been identified.

Monoclonal Gammopathy of Undetermined Significance (MGUS) is closely related. Here there is an overabundance of immunoglobulins in the blood. Approximately 1 in 100 individuals with MGUS go on to develop multiple myeloma each year. MGUS has no symptoms, so regular blood tests have to be done.

Currently, multiple myeloma cannot be cured. However, treatment can frequently assist to control the condition for several years. New medications, autologous stem cell transplantation, and improved supportive care have greatly improvedsurvival rates.

For diagnosing and initiating early treatment a set of criteria and defining events are necessary. This involves getting various blood tests and imaging.

Blood tests include:

Managing multiple myeloma requires a multidisciplinary approach of physicians, haematologists, radiologists, physiotherapists, dietitians and psychologists. The staging of the disease and symptoms dictate the treatment.

The therapy includes:

In first-line and relapsed settings, there is a combination of drugs used:

You may feel tired and nauseous and may also experience diarrhoea, constipation, numbness of hands and feet, mood changes, increased hunger, and sleep disturbances. A more thorough knowledge about the side effects can be obtained from your healthcare professional.

Experiences with multiple myeloma will vary from person to person. Some people have years to live with few symptoms. Others see a rapid deterioration in their condition. Using blood tests like albumin and beta-2-microglobulin, DNA tests can predict survival rates. As you discover how to cope with multiple myeloma, connect with doctors and support groups for guidance.

Ans: Yes, Kindly adhere to the doctors advice. It is absolutely important to get regular blood tests and other investigations as advised.

Ans: Eat healthy, exercise, protect yourself from infection and look after yourself. Take rest as and when needed.

LikeLoveHahaWowSadAngry

Excerpt from:
Multiple Myeloma - What It Is, Causes and Treatment Options ... - Metropolis Healthcare